0000000000427791

AUTHOR

Rainer Haas

showing 4 related works from this author

Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, gra…

1996

Differentiation induction therapy is being tested in myelodysplastic syndromes to ameliorate maturation defects and to restore normal hematopoietic function. To this end, 17 patients (eight with refractory anemia, two with refractory anemia and ring sideroblasts, and seven with refractory anemia and excess of blast cells) were treated with a combination of all-trans-retinoic acid (ATRA), granulocyte colony-stimulating factor (G-CSF), erythropoietin (EPO), and alpha-tocopherol for durations of 8-16 weeks. Absolute neutrophil counts increased in all patients; platelet counts increased in five patients with discontinuation of transfusion needs in two of four transfusion-dependent patients. Sti…

AdultMalemedicine.medical_specialtyCombination therapyTretinoinBone Marrowhemic and lymphatic diseasesInternal medicineGranulocyte Colony-Stimulating FactorMedicineHumansVitamin EErythropoietinAgedAged 80 and overHematologybusiness.industryMyelodysplastic syndromesHematologyGeneral MedicineMiddle Agedmedicine.diseaseGranulocyte colony-stimulating factorBlood Cell CountHematopoiesisHaematopoiesisEndocrinologymedicine.anatomical_structureErythropoietinMyelodysplastic SyndromesErythropoiesisDrug Therapy CombinationFemaleBone marrowbusinessmedicine.drugAnnals of hematology
researchProduct

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

2021

Abstract Background In a recent phase-III trial CPX-351 (Jazz Pharmaceuticals, Palo Alto, CA), a liposomal encapsulation of cytarabine and daunorubicin, has shown higher remission rates and longer overall survival (OS) in patients aged 60 to 75 years with AML with myelodysplasia-related changes (AML-MRC) or therapy-related AML (t-AML) in comparison to conventional 7+3 regimen. Based on this CPX-351 has been approved in the USA 2017 and in Europe 2018 for adult patients with newly-diagnosed AML-MRC or t-AML. Still, several issues such as age (<60 years), measurable residual disease (MRD), molecular subgroups and outcome after allo-HCT were not addressed in the phase-III trial. Aiming …

OncologyFirst line treatmentmedicine.medical_specialtybusiness.industryInternal medicineImmunologymedicineMyeloid leukemiaCell BiologyHematologybusinessBiochemistryBlood
researchProduct

Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.

2013

The revised IPSS (IPSS-R) was developed aiming at a better prognostication, taking into account patients treated with best supportive care. We herein validated this model on the basis of data from 1314 patients who received BSC only as well as patients who underwent induction chemotherapy (n=214) or allogeneic transplantation (n=167). We could demonstrate a clear distinction of the IPSS-R risk categories with regard to survival and risk of AML evolution in all patient cohorts. When comparing IPSS-R, IPSS, WHO prognostic scoring system (WPSS) and Duesseldorf score, the best results regarding the ability to predict survival were obtained by the IPSS-R.

OncologyAdultMalemedicine.medical_specialtyPediatricsCancer ResearchScoring systemAllogeneic transplantationSurvivalAdolescenturologic and male genital diseasesRisk AssessmentIPSS; IPSS-R; MDS; Prognosis; Survival; WPSS; Hematology; Oncology; Cancer ResearchRisk categoryYoung AdultRisk FactorsInternal medicinemedicineMDSHumansIn patientAgedAged 80 and overIPSS-Rbusiness.industryIPSSInduction chemotherapyReproducibility of ResultsHematologyMiddle AgedPrognosisSurvival AnalysisMulticenter studyOncologyInternational Prognostic Scoring SystemLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseMultivariate AnalysisDisease ProgressionWPSSFemalebusinessLeukemia research
researchProduct

Increased Risk of Catheter Colonization and Catheter-Related Infections in Severe Immunocompromized Patients with Multiple Myeloma Undergoing High-do…

1998

Catheter-related infections (CRI) are an important problem in medicine because of major consequences for treatment, prolongation of hospitalization and increasing therapy costs. Malignancies, immunodeficiency, severe burns and malnutrition compromise host defense. Studies to quantify the increased risk of CRI in immunocompromised patients are required. We analyzed the influence of immunoglobulin deficiency and high-dose glucocorticoid treatment in patients with multiple myeloma with regard to catheter colonization and CRI. In patients with multiple myeloma, central venous catheters (CVC) were significantly more frequently colonized (> 15 CFU) as compared to patients with other malignancies …

AdultMaleCatheterization Central Venousendocrine systemmedicine.medical_specialtyAdolescentStaphylococcusmedicine.medical_treatmentImmunologyAntineoplastic AgentsRisk AssessmentGastroenterologyImmunocompromised HostInternal medicineImmunopathologymedicineHumansImmunodeficiencyMultiple myelomaAgedRetrospective StudiesChemotherapybusiness.industryIncidence (epidemiology)Retrospective cohort studyMiddle Agedmedicine.diseaseSurgeryCatheterMultivariate AnalysisFemaleMultiple MyelomaComplicationbusinessZentralblatt für Bakteriologie
researchProduct